This rare adverse effect was witnessed in a small number of people post vaccine administration. A new study published in JAMA Internal Medicine looked at The Vaccine Adverse Event Reporting System ...

A US Food and Drug Administration (FDA) investigation of injection-site necrosis in some people who received the 23-valent pneumococcal vaccine has concluded that the benefits of the vaccine outweigh ...

Please provide your email address to receive an email when new articles are posted on . There were less than 0.2 cases of injection site necrosis per million 23-valent pneumococcal vaccine doses.

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the U.S. Centers for Disease Control and Prevention’s (CDC’s) Advisory ...

Merck MRK announced that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has unanimously voted to recommend MRK’s newly approved ...

The 20-valent pneumococcal conjugate vaccine (PCV20, or Prevnar 20) produced a non-inferior immune response in adults to the 13-valent vaccine (PCV13, or Prevnar 13), with an adequate safety profile, ...

Findings showed Capvaxive was noninferior to PPSV23 for each of the 12 serotypes present between the 2 vaccines. Topline data were announced from a phase 3 trial evaluating Merck’s 21-valent ...

Please provide your email address to receive an email when new articles are posted on . Over the past several years, adult pneumococcal vaccine recommendations have evolved based on the development of ...

The European Medicines Agency (EMA) has recommended granting marketing authorization for the pneumococcal vaccine Capvaxive (pneumococcal polysaccharide conjugate vaccine [21-valent]) intended to ...

National-level CDC surveillance data shows CAPVAXIVE covers the serotypes responsible for approximately 84% of invasive pneumococcal disease cases, compared to approximately 52% covered by PCV20 ...